Beximco Pharmaceuticals Ltd.
BXP | IL
Overview
Corporate Details
- ISIN(s):
- US0885792061
- LEI:
- 213800IMBBD6TIOQGB56
- Country:
- Bangladesh
- Address:
- N/A
- Website:
- https://www.beximcopharma.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-13 17:10 |
Report Publication Announcement
Request of Extension to Publish Q1 Results
|
English | 11.2 KB | ||
| 2025-11-04 08:25 |
Regulatory Filings
Change of Name to Beximco Pharmaceuticals PLC.
|
English | 10.8 KB | ||
| 2025-10-27 16:53 |
Report Publication Announcement
Request of Extension to Publish Financial Results
|
English | 11.3 KB |
Automate Your Workflow. Get a real-time feed of all Beximco Pharmaceuticals Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Beximco Pharmaceuticals Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Beximco Pharmaceuticals Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
United States of America
ENTO
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
United States of America
TRDA
South Korea
183490
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Sweden
ENZY
Develops ingestible therapeutic devices for weight management and targeted drug delivery.
Israel
EPIT
Israel
EPIT
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Sweden
EQL
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
United States of America
ERAS
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
United States of America
ERNA
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
France
ERYP
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR
United States of America
ESPR